Compare GRX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRX | NERV |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.5M | 166.4M |
| IPO Year | 2007 | 2014 |
| Metric | GRX | NERV |
|---|---|---|
| Price | $9.83 | $3.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 21.7K | ★ 120.5K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,175,600.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $2.06 |
| 52 Week High | $10.20 | $12.46 |
| Indicator | GRX | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 33.97 |
| Support Level | $9.49 | N/A |
| Resistance Level | $9.73 | $4.73 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 26.74 | 7.98 |
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.